The FDA Endocrine and Metabolic Drugs Advisory committee voted 13-7 today in favor of approving a new combination product, Contrave, for the treatment of obesity by prescription. Contrave is a combination of two drugs available for other indications, buproprion and naltrexone. This decision contrasts sharply with the outcome of three prior meetings this year of […]
